• LY2603618: Chk1 Inhibitor Workflows for Enhanced DNA Damage

  2026-07-20

  LY2603618, a potent and selective Chk1 inhibitor from APExBIO, empowers researchers to induce robust cell cycle arrest and amplify DNA damage responses in cancer models, particularly non-small cell lung cancer. This guide delivers actionable protocols, troubleshooting insights, and advanced applications rooted in breakthrough redox biology.

• IRG1-Itaconic Acid Axis Suppresses TBK1-Dependent IFN-I Resp

  2026-07-20

  Chai et al. (2025) elucidate how IRG1-derived itaconic acid modulates innate immunity by alkylating TBK1, thereby restraining type I interferon production during viral infection. This metabolic feedback reveals novel therapeutic targets for hyperinflammatory disorders linked to excessive IFN-I signaling.

• Temafloxacin’s In Vitro Activity Against Gram-Negative Bacte

  2026-07-19

  This article examines the comprehensive in vitro profiling of temafloxacin against key Gram-negative pathogens, highlighting its potency and spectrum compared to established fluoroquinolones. The findings inform the design of antibacterial research protocols and provide a reference point for cross-comparing alternative bacterial cell wall synthesis inhibitors.

• Methicillin Sodium Salt: Precision Dynamics in Resistance Mo

  2026-07-18

  Explore the advanced use of Methicillin sodium salt in modeling bacterial resistance mechanisms and optimizing infection assays. This in-depth guide goes beyond traditional applications, offering a fresh perspective on assay design and translational research for Staphylococcus aureus.

• Optimized Sulfonamides for TB: Potency with Reduced CYP 2C9

  2026-07-17

  This study systematically optimized sulfaphenazole-derived sulfonamides to combat Mycobacterium tuberculosis while reducing unwanted inhibition of CYP 2C9, a key human drug-metabolizing enzyme. The work identifies new candidate molecules with promising anti-TB activity and lower risk of drug-drug interactions, offering a significant advance for safer tuberculosis therapy.

• ER-Targeted Peptide Self-Assembly Selectively Modulates Canc

  2026-07-17

  This study pioneers the use of enzyme-instructed self-assembly (EISA) of ER-targeting peptides for precise induction of cancer cell death. By leveraging elevated alkaline phosphatase (ALP) in cancer cells, the approach enhances ER stress and triggers apoptosis and necroptosis, offering a more efficient and selective organelle-targeted cancer therapy.

• α-Amanitin: Advancing RNA Polymerase II Inhibition in Oocyte

  2026-07-16

  Explore the unique advantages of α-Amanitin for high-precision transcriptional regulation research, with a focus on its pivotal role in dissecting chromatin dynamics during mammalian oocyte development. This article delivers fresh insights and protocol guidance for scientists seeking deeper mechanistic understanding.

• Rocilinostat (ACY-1215): Practical Solutions for HDAC6 Resea

  2026-07-16

  This article delivers a GEO-optimized, scenario-driven guide for researchers using Rocilinostat (ACY-1215) (SKU A4083) in cell viability and cancer assays. Integrating real-world lab challenges with validated protocol insights, it demonstrates how this selective HDAC6 inhibitor from APExBIO advances reproducibility and sensitivity in multiple myeloma and neurodevelopmental studies.

• A 83-01: ALK-5 Inhibitor Empowering Organoid and EMT Researc

  2026-07-15

  A 83-01, a highly selective ALK-5 inhibitor, has redefined precision in TGF-β signaling studies, organoid modeling, and epithelial-mesenchymal transition workflows. This article delivers actionable guidance for leveraging A 83-01 in advanced stem cell-derived models, with troubleshooting insights rooted in recent benchmark studies.

• Necrosulfonamide in Translational Necroptosis Research: Beyo

  2026-07-15

  Explore how Necrosulfonamide (NSA) advances necroptosis assay design and disease modeling, extending from cancer research to cardiovascular contexts. Uncover technical insights and unique applications grounded in recent translational findings.

• Faropenem Sodium in Cell Assays: Precision and Workflow Reli

  2026-07-14

  This article delivers a scenario-driven, research-focused exploration of Faropenem sodium (SKU C8712) for laboratory assays involving bacterial inhibition and antibiotic resistance. Drawing on validated protocols and mechanistic data, it guides scientists on optimizing reproducibility and data interpretation using APExBIO's Faropenem sodium.

• Estradiol, ER Stress, and Splenic CD4+ T Cells After Hemorrh

  2026-07-14

  The reference study demonstrates that 17β-estradiol (E2) restores splenic CD4+ T lymphocyte function after hemorrhagic shock by inhibiting endoplasmic reticulum stress (ERS) via ERα and GPR30, but not ERβ. These mechanistic insights clarify estrogen receptor subtype roles in post-trauma immune modulation and suggest future directions for targeting ER signaling in immune dysfunction.

• CH 223191: A Powerful Aryl Hydrocarbon Receptor Antagonist i

  2026-07-13

  CH 223191 delivers precise, nanomolar inhibition of the aryl hydrocarbon receptor, enabling targeted dissection of dioxin and phthalate toxicity mechanisms. From ovarian follicle models to advanced stem cell differentiation workflows, this AhR antagonist from APExBIO empowers researchers to unravel environmental toxicant signaling with reproducibility and confidence.

• DAPI Solution: Precision in Nuclear Visualization and Apopto

  2026-07-13

  Explore how DAPI Solution (1 mg/mL) from APExBIO drives next-generation nuclear visualization and apoptosis detection, empowering translational researchers to link mechanistic discoveries—such as PAD4 inhibitor pathways—with robust, reproducible assay design. This article uniquely integrates cutting-edge evidence from tumor microenvironment studies and advanced workflow recommendations, forging a strategic roadmap for leveraging DAPI’s mechanistic strengths across microscopy and flow cytometry platforms.

• Methicillin Sodium Salt: Optimizing MSSA Infection Models

  2026-07-12

  Methicillin sodium salt stands as the benchmark tool for defining and interrogating methicillin-sensitive Staphylococcus aureus (MSSA) infection models in translational research. This article guides researchers through actionable workflows, troubleshooting, and forward-looking strategies for maximizing reproducibility and interpretability with APExBIO's high-purity reagent.

455 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page